keyword
MENU ▼
Read by QxMD icon Read
search

dementia pet

keyword
https://www.readbyqxmd.com/read/28334939/association-between-tau-deposition-and-antecedent-amyloid-%C3%AE-accumulation-rates-in-normal-and-early-symptomatic-individuals
#1
Duygu Tosun, Susan Landau, Paul S Aisen, Ronald C Petersen, Mark Mintun, William Jagust, Michael W Weiner
A long-term goal of our field is to determine the sequence of pathological events, which ultimately lead to cognitive decline and dementia. In this study, we first assessed the patterns of brain tau tangle accumulation (measured with the positron emission tomography tracer 18F-AV-1451) associated with well-established Alzheimer's disease factors in a cohort including cognitively healthy elderly individuals and individuals at early symptomatic stages of Alzheimer's disease. We then explored highly associated patterns of greater 18F-AV-1451 binding and increased annualized change in cortical amyloid-β plaques measured as florbetapir positron emission tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to what extent these multimodal pattern associations explained the variance in cognitive performance and clinical outcome measures, independently and jointly...
March 17, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/28331953/value-of-fdg-pet-scans-of-non-demented-patients-in-predicting-rates-of-future-cognitive-and-functional-decline
#2
Nare Torosyan, Kelsey Mason, Magnus Dahlbom, Daniel H S Silverman
PURPOSE: The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI). METHODS: Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer's Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer's disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores...
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28330509/chemically-treated-plasma-a%C3%AE-is-a-potential-blood-based-biomarker-for-screening-cerebral-amyloid-deposition
#3
Jong-Chan Park, Sun-Ho Han, Hyun Jin Cho, Min Soo Byun, Dahyun Yi, Young Min Choe, Seokjo Kang, Eun Sun Jung, Su Jin Won, Eun Hye Kim, Yu Kyeong Kim, Dong Young Lee, Inhee Mook-Jung
BACKGROUND: Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimer's disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks of AD pathogenesis in the brain. However, the association between plasma Aβ levels and AD diagnosis is still unclear due to the instability and inaccurate measurements of plasma Aβ levels in the blood of patients with AD. If a consistent value of plasma Aβ from the blood can be obtained, this might help determine whether plasma Aβ is a potential biomarker for AD diagnosis...
March 22, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28322203/associations-between-%C3%AE-amyloid-and-white-matter-hyperintensities-a-systematic-review
#4
REVIEW
Austyn Roseborough, Joel Ramirez, Sandra E Black, Jodi D Edwards
INTRODUCTION: This systematic review synthesizes current evidence for associations between cortical β-amyloid, visualized on amyloid positron emission tomography imaging, and white matter hyperintensity (WMH) burden on magnetic resonance imaging in healthy elderly adults and individuals with cognitive impairment and dementia. METHODS: Following PRISMA systematic review guidelines, we systematically searched MEDLINE, Embase, Cochrane, and PsycINFO databases from January 2000 to September 2015...
March 16, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/28317648/clinical-validity-of-brain-fluorodeoxyglucose-positron-emission-tomography-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#5
REVIEW
Valentina Garibotto, Karl Herholz, Marina Boccardi, Agnese Picco, Andrea Varrone, Agneta Nordberg, Flavio Nobili, Osman Ratib
The use of Alzheimer's disease (AD) biomarkers is supported in diagnostic criteria, but their maturity for clinical routine is still debated. Here, we evaluate brain fluorodeoxyglucose positron emission tomography (FDG PET), a measure of cerebral glucose metabolism, as a biomarker to identify clinical and prodromal AD according to the framework suggested for biomarkers in oncology, using homogenous criteria with other biomarkers addressed in parallel reviews. FDG PET has fully achieved phase 1 (rational for use) and most of phase 2 (ability to discriminate AD subjects from healthy controls or other forms of dementia) aims...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28315844/cerebral-glucose-metabolism-and-cognition-in-newly-diagnosed-parkinson-s-disease-icicle-pd-study
#6
M J Firbank, A J Yarnall, R A Lawson, G W Duncan, T K Khoo, G S Petrides, J T O'Brien, R A Barker, R J Maxwell, D J Brooks, D J Burn
OBJECTIVE: To assess reductions of cerebral glucose metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their associations with cognitive decline. METHODS: FDG-PET was performed on a cohort of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls. PD participants were scanned while on their usual dopaminergic medication. Cognitive testing was performed at baseline, and after 18 months using the Cognitive Drug Research (CDR) and Cambridge Neuropsychological Test Automated Battery (CANTAB) computerised batteries, the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA)...
April 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28315409/in-vivo-tau-pet-imaging-in-dementia-pathophysiology-radiotracer-quantification-and-a-systematic-review-of-clinical-findings
#7
REVIEW
Benjamin Hall, Elijah Mak, Simon Cervenka, Franklin I Aigbirhio, James B Rowe, John T O'Brien
In addition to the deposition of β-amyloid plaques, neurofibrillary tangles composed of aggregated hyperphosphorylated tau are one of the pathological hallmarks of Alzheimer's disease and other neurodegenerative disorders. Until now, our understanding about the natural history and topography of tau deposition has only been based on post-mortem and cerebrospinal fluid studies, and evidence continues to implicate tau as a central driver of downstream neurodegenerative processes and cognitive decline. Recently, it has become possible to assess the regional distribution and severity of tau burden in vivo with the development of novel radiotracers for positron emission tomography (PET) imaging...
March 14, 2017: Ageing Research Reviews
https://www.readbyqxmd.com/read/28304299/low-florbetapir-pet-uptake-and-normal-a%C3%AE-1%C3%A2-%C3%A2-42-cerebrospinal-fluid-in-an-app-ala-713thr-mutation-carrier
#8
Gemma Lombardi, Valentina Berti, Andrea Tedde, Silvia Bagnoli, Irene Piaceri, Cristina Polito, Giulia Lucidi, Camilla Ferrari, Andrea Ginestroni, Marco Moretti, Alberto Pupi, Benedetta Nacmias, Sandro Sorbi
According to the literature, the APP Ala713Thr mutation is associated with Alzheimer's disease and cerebral amyloid angiopathy. We describe a case of dementia clinically compatible with frontotemporal dementia in an APP Ala713Thr mutation carrier in which both [18F]Florbetapir PET uptake and Aβ1-42 cerebrospinal fluid levels were normal. Further evidences are required to establish if this association is only incidental.
March 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28304289/episodic-memory-dysfunction-in%C3%A2-behavioral-variant-frontotemporal-dementia-a-clinical-and-fdg-pet-study
#9
Marta Fernández-Matarrubia, Jordi A Matías-Guiu, María Nieves Cabrera-Martín, Teresa Moreno-Ramos, María Valles-Salgado, José Luis Carreras, Jorge Matías-Guiu
BACKGROUND: Episodic memory disturbance is still considered as an exclusion criterion for behavioral variant frontotemporal dementia (bvFTD), but growing evidence suggests that memory can be impaired. OBJECTIVE: Our main purposes were to assess episodic memory in a group of bvFTD patients comparatively with Alzheimer's disease (AD) patients, and analyze the relationship between episodic memory and brain metabolism measured using positron emission tomography imaging with 18F-fluorodeoxyglucose (FDG-PET)...
March 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28303161/a-systematic-review-of-intervention-studies-examining-nutritional-and-herbal-therapies-for-mild-cognitive-impairment-and-dementia-using-neuroimaging-methods-study-characteristics-and-intervention-efficacy
#10
REVIEW
Genevieve Z Steiner, Danielle C Mathersul, Freya MacMillan, David A Camfield, Nerida L Klupp, Sai W Seto, Yong Huang, Mark I Hohenberg, Dennis H Chang
Neuroimaging facilitates the assessment of complementary medicines (CMs) by providing a noninvasive insight into their mechanisms of action in the human brain. This is important for identifying the potential treatment options for target disease cohorts with complex pathophysiologies. The aim of this systematic review was to evaluate study characteristics, intervention efficacy, and the structural and functional neuroimaging methods used in research assessing nutritional and herbal medicines for mild cognitive impairment (MCI) and dementia...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28288263/neurofibrillary-tangle-stage-and-the-rate-of-progression-of-alzheimer-symptoms-modeling-using-an-autopsy-cohort-and-application-to-clinical-trial-design
#11
Jing Qian, Bradley T Hyman, Rebecca A Betensky
Importance: The heterogeneity of rate of clinical progression among patients with Alzheimer disease leads to difficulty in providing clinical counseling and diminishes the power of clinical trials using disease-modifying agents. Objective: To gain a better understanding of the factors that affect the natural history of progression in Alzheimer disease for the purpose of improving both clinical care and clinical trial design. Design, Setting, and Participants: A longitudinal cohort study of aging from 2005 to 2014 in the National Alzheimer Coordinating Center...
March 13, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28287184/a-disease-severity-index-to-identify-individuals-with-subjective-memory-decline-who-will-progress-to-mild-cognitive-impairment-or-dementia
#12
Daniel Ferreira, Farshad Falahati, Cecilia Linden, Rachel F Buckley, Kathryn A Ellis, Greg Savage, Victor L Villemagne, Christopher C Rowe, David Ames, Andrew Simmons, Eric Westman
Subjective memory decline (SMD) is a heterogeneous condition. While SMD might be the earliest sign of Alzheimer's disease (AD), it also occurs in aging and various neurological, medical, and psychiatric conditions. Identifying those with higher risk to develop dementia is thus a major challenge. We tested a novel disease severity index generated by multivariate data analysis with numerous structural MRI measures as input. The index was used to identify SMD individuals with high risk of progression to mild cognitive impairment (MCI) or AD...
March 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28285306/extremely-low-prevalence-of-amyloid-positron-emission-tomography-positivity-in-parkinson-s-disease-without-dementia
#13
Kyoko Mashima, Daisuke Ito, Masashi Kameyama, Takashi Osada, Hajime Tabuchi, Yoshihiro Nihei, Takahito Yoshizaki, Eri Noguchi, Mariko Tanikawa, Takashi Iizuka, Yugaku Date, Yuji Ogata, Tadaki Nakahara, Yu Iwabuchi, Masahiro Jinzaki, Koji Murakami, Norihiro Suzuki
BACKGROUND: Most cases of dementia with Lewy bodies (DLB) show Alzheimer's disease pathology-like senile plaques and neurofibrillary tangles. Several studies have also revealed a high prevalence of positive amyloid imaging with positron emission tomography (PET) in DLB and moderate prevalence in Parkinson's disease (PD) with dementia. However, it remains unclear in PD without dementia as to when the brain β amyloid (Aβ) burden begins and progresses. Our study aimed to determine the prevalence of Aβ deposition in PD without dementia using amyloid PET...
March 11, 2017: European Neurology
https://www.readbyqxmd.com/read/28283594/cued-memory-decline-in-biomarker-defined-preclinical-alzheimer-disease
#14
Kathryn V Papp, Dorene M Rentz, Elizabeth C Mormino, Aaron P Schultz, Rebecca E Amariglio, Yakeel Quiroz, Keith A Johnson, Reisa A Sperling
OBJECTIVE: To determine whether a decline in cued recall is observable in the preclinical stage of Alzheimer disease (AD) in clinically normal older adults with elevated β-amyloid (Aβ) burden on PET imaging. METHODS: Clinically normal older adults underwent baseline neuroimaging (PET to assess Aβ(+/-) status and MRI) and annual neuropsychological testing. Cox proportional hazards models were used to assess the relative risk of cued memory decline (drop of 1, 2, 3, or 4 points on the total score of the Free and Cued Selective Reminding Test) in relation to neuroimaging measures, functional status, age, sex, and education...
March 10, 2017: Neurology
https://www.readbyqxmd.com/read/28280223/progressive-disgregation-of-brain-networking-from-normal-aging-to-alzheimer-s-disease-independent-component-analysis-on-fdg-pet-data
#15
Marco Me Pagani, Alessandro Giuliani, Johanna Öberg, Fabrizio De Carli, Silvia Morbelli, Nicola Girtler, Francesca Bongioanni, Dario Arnaldi, Jennifer Accardo, Matteo Bauckneht, Andrea Chincarini, Gianmario Sambuceti, Cathrine Jonsson, Flavio Nobili
Brain connectivity has been assessed in several neurodegenerative disorders investigating the mutual correlations between pre-determined regions or nodes. The selective breakdown of brain networks during the progression from the normal aging (NA) to Alzheimer's Disease (AD) has also been observed. We implemented Independent Component Analysis (ICA) on 18F-FDG-PET data in five groups of subjects with cognitive state ranging from NA to AD dementia, including mild cognitive impairment patients not converting (ncMCI) and converting (MCI) to mild AD dementia, in order to disclose the spatial distribution of the independent components (ICs) in each cognitive state, and their accuracy in discriminating the groups...
March 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28269787/cognitive-composites-domain-scores-related-to-neuroimaging-biomarkers-within-probable-amnestic-mild-cognitive-impairment-storage-subtype
#16
Ana Espinosa, Montserrat Alegret, Pedro Pesini, Sergi Valero, Asunción Lafuente, Mar Buendía, Itziar San José, Marta Ibarria, Miguel A Tejero, Joan Giménez, Susana Ruiz, Isabel Hernández, Francesc Pujadas, Pablo Martínez-Lage, Josep Munuera, Javier Arbizu, Lluis Tárraga, Suzanne B Hendrix, Agustín Ruiz, James T Becker, Susan M Landau, Oscar Sotolongo-Grau, Manuel Sarasa, Mercè Boada
The probable-amnestic (Pr-a) mild cognitive impairment (MCI)-storage subtype is a phenotype with 8.5 times more risk of conversion to dementia, mainly Alzheimer's disease (AD), than the possible non-amnestic (Pss-na) MCI. The aim of this study was to find the optimized cognitive composites (CCs) domain scores most related to neuroimaging biomarkers within Pr-aMCI-storage subtype patients. The Fundació ACE (ACE) study with 20 Pr-aMCI-storage subtype subjects (MCI) were analyzed. All subjects underwent a neuropsychological assessment, a structural MRI, FDG-PET, and PIB-PET...
February 25, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28253276/clinical-and-neuroimaging-characteristics-of-chinese-dementia-with-lewy-bodies
#17
Shuai Liu, Xiao-Dan Wang, Ying Wang, Zhihong Shi, Li Cai, Shuling Liu, Tong Han, Yuying Zhou, Xinping Wang, Shuo Gao, Yong Ji
Dementia with Lewy bodies (DLB) is the second most common subtype of degenerative dementia. To our knowledge, available information about the clinical features of DLB in China remains limited. Our study therefore aimed to address this issue. Thirty-seven Chinese patients with probable DLB were recruited for this study. All subjects underwent neuropsychological assessment by trained neurologists, as well as undergoing MRI, 11C-PIB PET scans for Aβ deposition and 18F-FDG PET scans for regional cerebral glucose metabolism...
2017: PloS One
https://www.readbyqxmd.com/read/28244178/evaluation-of-an-optimized-18-f-fluoro-deoxy-glucose-positron-emission-tomography-voxel-wise-method-to-early-support-differential-diagnosis-in-atypical-parkinsonian-disorders
#18
S P Caminiti, P Alongi, L Majno, M A Volontè, C Cerami, L Gianolli, G Comi, D Perani
BACKGROUND AND PURPOSE: Atypical Parkinsonian disorders (APD) frequently overlap in clinical presentations, making the differential diagnosis challenging in the early stages. The present study aimed to evaluate the accuracy of the [(18) F]fluoro-deoxy-glucose positron emission tomography Statistical Parametric Mapping (SPM) optimized procedure in supporting the early and differential diagnosis of APD. METHODS: Seventy patients with possible APD were retrospectively included from a large clinical cohort...
February 28, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28240664/creutzfeldt-jakob-disease-mimicking-alzheimer-disease-and-dementia-with-lewy-bodies-findings-of-fdg-pet-with-3-dimensional-stereotactic-surface-projection
#19
Nobuhiko Miyazawa
A 78-year-old man received a diagnosis of sporadic Creutzfeldt-Jakob disease based on symptoms and findings of MRI, FDG PET, and cerebrospinal fluid markers. PET with 3-dimensional stereotactic surface projection (3D-SSP) showed that the distribution of hypometabolism mimicked that of Alzheimer disease. A 68-year-old woman was treated under a diagnosis of convulsion. Findings of MRI, PET, familial history, and cerebrospinal fluid markers revealed familial Creutzfeldt-Jakob disease. FDG PET with 3D-SSP disclosed that the hypometabolic pattern mimicked that of dementia with Lewy bodies...
February 24, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28240379/different-apathy-clinical-profile-and-neural-correlates-in-behavioral-variant-frontotemporal-dementia-and-alzheimer-s-disease
#20
Marta Fernández-Matarrubia, Jordi A Matías-Guiu, María Nieves Cabrera-Martín, Teresa Moreno-Ramos, María Valles-Salgado, José Luis Carreras, Jorge Matías-Guiu
OBJECTIVES: Apathy is one of the most common and disabling syndromes of dementia. Clinical apathy expression and neuroanatomical basis of apathy seem to differ between behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD), although evidence is scarce and poorly understood. Our main purposes were to compare the clinical apathy profile from patients with bvFTD and AD and analyze the relationship between apathy and brain metabolism measured using positron emission tomography imaging with (18) F fluorodeoxyglucose (FDG-PET)...
February 27, 2017: International Journal of Geriatric Psychiatry
keyword
keyword
68325
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"